After sixteen years of leading project and portfolio management organizations in small and medium size biotech companies, Dara Lockert founded Spannerwerks in 2015 to provide on-demand teams to growing companies. With a foundation in laboratory research, good project management and years of leadership responsibility in biologics, immunotherapy, vaccine development and genomics, Dara has built a team of experienced consultants specializing in enabling biotech founders and R&D teams to design effective regulatory strategies, prepare for Investigational Drug (IND) submissions, set up and execute clinical trials, and plan for post approval success.
Spannerwerks recently announced they have been acquired by Alloy Therapeutics, Inc. (“Alloy”) , a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies. Spannerwerks will operate as a wholly owned subsidiary of Alloy, continuing to serve clients under the Spannerwerks name. Dara joined Alloy and will continue to serve as CEO of Spannerwerks and serve as part of the Alloy leadership team.